Phase II study of rituximab in the treatment of cladribine-failed patients (pts.) with hairy cell leukemia (HCL).

被引：0
|
作者：
Nieva, J
Bethel, K
Baker, T
Saven, A
机构：
[1] Scripps Res Inst, Dept Pathol, La Jolla, CA USA
[2] Scripps Canc Ctr, La Jolla, CA USA
[3] Cecil H & Ida M Green Canc Ctr, La Jolla, CA USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1535
引用
收藏
页码：364A / 365A
页数：2
相关论文
共 50 条
  • [21] Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence
    Else, Monica
    Dearden, Claire E.
    Matutes, Estella
    Forconi, Francesco
    Lauria, Francesco
    Ahmad, Humayun
    Kelly, Susan
    Liyanage, Anandika
    Ratnayake, Vijitha
    Shankari, Jagadeesan
    Whalley, Ioana
    Catovsky, Daniel
    LEUKEMIA & LYMPHOMA, 2011, 52 : 75 - 78
  • [22] Vemurafenib in Advanced Patients with Hairy Cell Leukemia (HCL): Results of the Acse Phase II Trial
    Troussard, Xavier
    Montane, Laure
    Tiab, Mourad
    Chaleteix, Carine
    Grulois, Isabelle
    Lindet, Clothilde
    Legoupil, Delphine
    Kohser, Frederic
    Pannier, Diane
    Maloisel, Frederic
    Bories, Pierre
    Oukhatar, Celine A. I. T.
    Labouret, Natalie Hoog
    Blay, Jean-Yves
    BLOOD, 2017, 130
  • [23] Comparative study between intravenous and subcutaneous administration of cladribine in treatment of hairy cell leukemia patients
    Nehad M. Tawfik
    Aml Soliman Nasr
    Comparative Clinical Pathology, 2012, 21 (6) : 1269 - 1274
  • [24] Rituximab For Hairy-Cell Leukemia (HCL): A Multicentric Retrospective Study Of 41 Cases
    Leclerc, Mathieu
    Suarez, Felipe
    Noel, Marie-Pierre
    Vekhoff, Anne
    Troussard, Xavier
    Claisse, Jean-Francois
    Thieblemont, Catherine
    Maloisel, Frederic
    Beguin, Yves
    Tamburini, Jerome
    Barbe, Coralie
    Delmer, Alain
    BLOOD, 2013, 122 (21)
  • [25] Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial
    Chihara, Dai
    Kantarjian, Hagop
    O'Brien, Susan
    Jorgensen, Jeffrey
    Pierce, Sherry
    Faderl, Stefan
    Ferrajoli, Alessandra
    Poku, Rebecca
    Jain, Preetesh
    Thompson, Phillip
    Brandt, Mark
    Luthra, Rajyalakshmi
    Burger, Jan
    Keating, Michael
    Ravandi, Farhad
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (05) : 760 - 766
  • [26] Extended follow-up of patients with hairy cell leukemia after treatment with cladribine
    Goodman, GR
    Burian, C
    Koziol, JA
    Saven, A
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (05) : 891 - 896
  • [27] Complete eradication of minimal residual disease (MRD) in patients with hairy cell leukemia (HCL) after cladribine (2CDA) followed by an extended course of rituximab
    Kashani, FR
    O'Brien, S
    Michael, K
    Jones, D
    Faderl, S
    Ferrajoli, A
    Wierda, W
    Odinga, S
    Pierce, S
    Koller, C
    Verstovsek, S
    Jeffrey, J
    Kantarjian, H
    BLOOD, 2005, 106 (11) : 911A - 911A
  • [28] Fludarabine and Rituximab (FR) Is a Safe and Effective Treatment Alternative for Relapsed or Refractory Hairy Cell Leukemia (HCL)
    Gerrie, Alina S.
    Zypchen, Leslie N.
    Connors, Joseph M.
    BLOOD, 2010, 116 (21) : 1019 - 1019
  • [29] Phase-II-study of rituximab in combination with fludarabine in patients (pts) with chronic lymphocytic leukemia (CLL).
    Schulz, H
    Klein, SK
    Rehwald, U
    Reiser, M
    Ibach, S
    Aulitzky, WE
    Hensel, M
    Herold, M
    Huhn, D
    Knauf, U
    Hallek, M
    Diehl, V
    Engert, A
    BLOOD, 2001, 98 (11) : 364A - 364A
  • [30] 2-chlorodeoxyadenosine (CDA) by subcutaneous bolus injection: A phase II study in hairy cell leukemia (HCL).
    vonRohr, A
    Bacchi, M
    Fey, MF
    Hess, U
    Tichelli, A
    Piguet, D
    Frickhofen, N
    Schirmer, M
    Wernli, M
    Zulian, G
    Marini, G
    Cerny, T
    Tobler, A
    BLOOD, 1995, 86 (10) : 1386 - 1386
12345